摘要
免疫性血细胞减少症是对所有体液或细胞免疫异常导致的血细胞减少性疾病的总称,其共同免疫机制决定了免疫抑制治疗的重要性。西罗莫司作为针对哺乳动物雷帕霉素靶蛋白的免疫抑制剂,通过调整Treg细胞诱导免疫耐受,在难治性免疫性血细胞减少症中具有应用前景。本文主要就西罗莫司在原发性免疫性血细胞减少症治疗中的作用机制、应用进展及可能的不良反应进行综述。
Autoimmune cytopenia is a general term for all hemocytopenia diseases caused by humoral or cellular immunity abnormalities,and its common immune mechanism determines the importance of immunosuppressive therapy.Sirolimus,as an immunosuppressant against of mTOR,induces immune tolerance by adjusting Treg cells,which has application prospect in the treatment of refractory autoimmune cytopenia.This article reviews the mechanism,application,and possible adverse reactions of sirolimus in the treatment of idiopathic autoimmune cytopenia.
作者
王亚茹
马艳萍
秦小琪
WANG Ya-Ru;MA Yan-Ping;Qin Xiao-Qi(Department of Hematology,The Second Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2021年第5期1667-1670,共4页
Journal of Experimental Hematology
基金
山西省重点研发计划项目(201903D321099)。
